PapersFlow Research Brief
Neurological diseases and metabolism
Research Guide
What is Neurological diseases and metabolism?
Neurological diseases and metabolism refers to neurodegenerative disorders characterized by brain iron accumulation linked to genetic mutations in genes such as Pantothenate Kinase (PANK2), Coenzyme A biosynthesis pathways, and Phospholipase A2 (PLA2G6), often presenting with clinical, radiographic, and neuroimaging features including parkinsonism and mitochondrial dysfunction.
This field encompasses 25,348 papers on neurodegeneration associated with brain iron accumulation and metabolic disruptions in pathways like Coenzyme A biosynthesis. Research highlights genetic mutations in PANK2 and PLA2G6 as central to disorders showing ferritin buildup and neuroimaging abnormalities. Growth rate over the past 5 years is not available in the data.
Topic Hierarchy
Research Sub-Topics
Pantothenate Kinase-Associated Neurodegeneration
This sub-topic studies PANK2 mutations causing coenzyme A deficiency, leading to iron accumulation in basal ganglia. Researchers characterize clinical phenotypes, neuroimaging hallmarks like eye-of-the-tiger sign, and potential therapies.
PLA2G6-Associated Neurodegeneration
Researchers investigate phospholipase A2 mutations disrupting lipid homeostasis and causing dystrophic neurites with iron deposition. Focus includes atypical parkinsonism phenotypes and advanced MRI biomarkers.
Neuroferritinopathy and Brain Iron Accumulation
This area examines FTL1 mutations impairing ferritin function, resulting in iron dysregulation and movement disorders. Clinical and genetic studies correlate with neuroimaging patterns like cystic degeneration.
Neuroimaging in Neurodegeneration with Brain Iron Accumulation
Researchers develop quantitative MRI susceptibility mapping and R2* relaxometry to detect and monitor NBIA pathology. Longitudinal studies track progression and treatment responses across genetic subtypes.
Mitochondrial Dysfunction in NBIA Disorders
This sub-topic explores how NBIA gene defects impair mitochondrial bioenergetics, iron-sulfur cluster biogenesis, and oxidative stress. Biochemical and cellular models test antioxidants and metabolic rescue strategies.
Why It Matters
Studies in this field inform diagnosis and potential treatments for disorders like Parkinson's disease, where brain iron accumulation contributes to pathology progression. For instance, Heiko Braak et al. (2002) in "Staging of brain pathology related to sporadic Parkinson’s disease" outlined a six-stage progression of Lewy body pathology from the brainstem to neocortex, correlating with clinical symptoms in over 10,000 citations worth of referenced works. Maria Grazia Spillantini et al. (1997) in "α-Synuclein in Lewy bodies" identified α-synuclein as the primary component of Lewy bodies, advancing understanding of protein aggregation in Parkinson's and related metabolic dysfunctions. Ronald B. Postuma et al. (2015) established MDS clinical diagnostic criteria for Parkinson's disease in "MDS clinical diagnostic criteria for Parkinson's disease", enabling precise identification of cases with iron-related neurodegeneration for targeted interventions.
Reading Guide
Where to Start
"Staging of brain pathology related to sporadic Parkinson’s disease" by Braak et al. (2002) provides an accessible entry with its clear six-stage model of pathology progression, foundational for understanding metabolic neurodegeneration.
Key Papers Explained
Braak et al. (2002) "Staging of brain pathology related to sporadic Parkinson’s disease" establishes progression stages building on Spillantini et al. (1997) "α-Synuclein in Lewy bodies", which identifies α-synuclein in inclusions; Polymeropoulos et al. (1997) "Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease" extends this to genetics; Postuma et al. (2015) "MDS clinical diagnostic criteria for Parkinson's disease" applies these for diagnosis; Neumann et al. (2006) "Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis" connects to ALS/FTD metabolism.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research centers on genetic mutations in PANK2, Coenzyme A, and PLA2G6 with no recent preprints or news available; frontiers involve neuroimaging of ferritin and mitochondrial dysfunction in parkinsonism, extending top papers' pathology models.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Staging of brain pathology related to sporadic Parkinson’s dis... | 2002 | Neurobiology of Aging | 10.5K | ✕ |
| 2 | α-Synuclein in Lewy bodies | 1997 | Nature | 8.2K | ✓ |
| 3 | Mutation in the α-Synuclein Gene Identified in Families with P... | 1997 | Science | 8.1K | ✕ |
| 4 | MDS clinical diagnostic criteria for Parkinson's disease | 2015 | Movement Disorders | 6.9K | ✓ |
| 5 | Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and ... | 2006 | Science | 6.4K | ✕ |
| 6 | Prions | 1998 | Proceedings of the Nat... | 5.3K | ✕ |
| 7 | El Escorial revisited: Revised criteria for the diagnosis of a... | 2000 | Amyotrophic Lateral Sc... | 5.3K | ✕ |
| 8 | Amyloid plaque core protein in Alzheimer disease and Down synd... | 1985 | Proceedings of the Nat... | 4.4K | ✓ |
| 9 | A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of C... | 2011 | Neuron | 4.4K | ✓ |
| 10 | Motor Neuron Degeneration in Mice that Express a Human Cu,Zn S... | 1994 | Science | 4.1K | ✕ |
Frequently Asked Questions
What genetic mutations are associated with brain iron accumulation in neurological diseases?
Mutations in Pantothenate Kinase (PANK2), Coenzyme A biosynthesis genes, and Phospholipase A2 (PLA2G6) drive neurodegeneration with brain iron accumulation. These alterations disrupt metabolism, leading to ferritin buildup and parkinsonism. Neuroimaging reveals characteristic features in affected patients.
How does α-synuclein relate to metabolism in Parkinson's disease?
α-Synuclein forms Lewy bodies, a hallmark of Parkinson's disease, as shown by Spillantini et al. (1997) in "α-Synuclein in Lewy bodies". This aggregation links to metabolic dysfunction and iron accumulation in neurodegeneration. The protein's role persists across sporadic and familial cases.
What are the diagnostic criteria for Parkinson's disease involving metabolic neurodegeneration?
Postuma et al. (2015) in "MDS clinical diagnostic criteria for Parkinson's disease" provide Movement Disorder Society criteria for clinical diagnosis. These benchmarks support research and guide identification of iron accumulation-related parkinsonism. Expert consensus ensures reliability across 6882 citations.
What is the pathology staging in sporadic Parkinson’s disease?
Braak et al. (2002) in "Staging of brain pathology related to sporadic Parkinson’s disease" describe six stages of Lewy body spread from medulla oblongata to neocortex. Early stages involve brainstem iron-related changes preceding motor symptoms. This model, with 10458 citations, links metabolism to progression.
How do mutations in α-Synuclein contribute to familial Parkinson's disease?
Polymeropoulos et al. (1997) in "Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease" identified a mutation in the α-Synuclein gene in Italian kindreds with 2% lifetime incidence. This familial aggregation ties to metabolic pathways in neurodegeneration. The finding spans 8128 citations.
What role does TDP-43 play in ALS and frontotemporal degeneration?
Neumann et al. (2006) in "Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis" identified TDP-43 as the ubiquitinated protein in inclusions. This tau- and α-synuclein-negative pathology relates to metabolic stress in motor neuron diseases. The discovery holds across 6430 citations.
Open Research Questions
- ? How do PANK2 mutations specifically disrupt Coenzyme A biosynthesis to cause brain iron accumulation?
- ? What metabolic interventions can mitigate PLA2G6-related mitochondrial dysfunction in parkinsonism?
- ? How does ferritin dysregulation interact with α-synuclein aggregation in sporadic versus familial Parkinson's?
- ? Can neuroimaging biomarkers predict progression in Pantothenate Kinase-associated neurodegeneration?
- ? What is the precise mechanism linking genetic mutations to radiographic features of brain iron disorders?
Recent Trends
The field maintains 25,348 papers with no specified 5-year growth rate; no recent preprints or news coverage in the last 12 months indicates steady focus on established works like Braak et al. at 10458 citations and Spillantini et al. (1997) at 8162 citations.
2002Research Neurological diseases and metabolism with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurological diseases and metabolism with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers